Carlyle
Latest statistics and disclosures from Carlyle Group's latest quarterly 13F-HR filing:
- Top 5 stock holdings are QDEL, ZI, SLNO, VTRU, GETY, and represent 88.15% of Carlyle Group's stock portfolio.
- Added to shares of these 3 stocks: SLNO (+$23M), CSLR, SYRE.
- Started 1 new stock position in SYRE.
- Reduced shares in these 3 stocks: , ZI (-$21M), GETY.
- Sold out of its position in MKSI.
- Carlyle Group was a net seller of stock by $-301M.
- Carlyle Group has $2.1B in assets under management (AUM), dropping by -9.82%.
- Central Index Key (CIK): 0001527166
Tip: Access up to 7 years of quarterly data
Positions held by Carlyle consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Carlyle Group
Carlyle Group holds 25 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Quidel Corp (QDEL) | 44.2 | $918M | 13M | 73.70 |
|
|
| ZoomInfo Technologies Common Stock (ZI) | 31.3 | $652M | -3% | 35M | 18.49 |
|
| Soleno Therapeutics (SLNO) | 5.5 | $115M | +24% | 2.9M | 40.25 |
|
| Vitru Ord (VTRU) | 4.7 | $98M | 6.2M | 15.76 |
|
|
| Getty Images Holdings Cl A Com (GETY) | 2.4 | $49M | -3% | 9.4M | 5.25 |
|
| Verona Pharma Sponsored Ads (VRNA) | 2.3 | $49M | 2.5M | 19.86 |
|
|
| GDS Hldgs Sponsored Ads (GDS) | 1.8 | $37M | 4.1M | 9.12 |
|
|
| Phathom Pharmaceuticals (PHAT) | 1.5 | $32M | 3.5M | 9.13 |
|
|
| Hillevax (HLVX) | 1.4 | $30M | 1.8M | 16.05 |
|
|
| Vera Therapeutics Cl A (VERA) | 1.1 | $22M | 1.4M | 15.37 |
|
|
| Seacor Marine Hldgs (SMHI) | 0.8 | $17M | 1.3M | 12.59 |
|
|
| Invitation Homes (INVH) | 0.8 | $16M | 478k | 34.11 |
|
|
| Cubesmart (CUBE) | 0.5 | $10M | 221k | 46.35 |
|
|
| Spruce Biosciences (SPRB) | 0.4 | $8.4M | 2.9M | 2.89 |
|
|
| Jasper Therapeutics | 0.3 | $6.7M | 8.8M | 0.76 |
|
|
| Reneo Pharmaceuticals (RPHM) | 0.2 | $4.3M | 2.7M | 1.60 |
|
|
| Complete Solaria (CSLR) | 0.2 | $4.3M | +10% | 2.7M | 1.55 |
|
| Adicet Bio (ACET) | 0.2 | $4.0M | 2.1M | 1.88 |
|
|
| Smart Sh Global Ads (EM) | 0.1 | $2.4M | 4.8M | 0.50 |
|
|
| Effector Therapeutics | 0.1 | $2.2M | 4.8M | 0.46 |
|
|
| Nucana Sponsored Adr (NCNA) | 0.0 | $967k | 3.3M | 0.29 |
|
|
| Meta Data Sponsored Ads (AIU) | 0.0 | $306k | 314k | 0.97 |
|
|
| Spyre Therapeutics Com New (SYRE) | 0.0 | $204k | NEW | 9.6k | 21.20 |
|
| Exicure Com New (XCUR) | 0.0 | $163k | 282k | 0.58 |
|
|
| Molecular Templates Com New (MTEM) | 0.0 | $49k | 13k | 3.70 |
|
Past Filings by Carlyle Group
SEC 13F filings are viewable for Carlyle Group going back to 2012
- Carlyle Group 2023 Q4 filed Feb. 2, 2024
- Carlyle Group 2023 Q3 filed Nov. 3, 2023
- Carlyle Group 2023 Q2 filed Aug. 4, 2023
- Carlyle Group 2023 Q1 filed May 5, 2023
- Carlyle Group 2022 Q4 filed Feb. 10, 2023
- Carlyle Group 2022 Q3 filed Nov. 10, 2022
- Carlyle Group 2022 Q2 filed Aug. 12, 2022
- Carlyle Group 2022 Q1 filed May 13, 2022
- Carlyle Group 2021 Q4 filed Feb. 11, 2022
- Carlyle Group 2021 Q3 filed Nov. 12, 2021
- Carlyle Group 2021 Q2 filed Aug. 12, 2021
- Carlyle Group 2021 Q1 filed May 14, 2021
- Carlyle Group 2020 Q4 filed Feb. 12, 2021
- Carlyle Group 2020 Q3 filed Nov. 13, 2020
- Carlyle Group 2020 Q2 filed Aug. 13, 2020
- Carlyle Group 2020 Q1 filed May 13, 2020